Please select the option that best describes you:
Topics:
Hematologic Malignancies • Pediatric Hematology/Oncology • Internal Medicine • ALL • Hematology • ASH 2024
With the data from AALL1731, how is blinatumomab being implemented for SR and HR leukemia patients not previously planned/randomized to receive blinatumomab?
Based on AALL1731, if in maintenance, is there a certain point at which it is incorporated, or a certain maintenance cycle which it is no longer offered after? Is blinatumomab being offered to SR-Fav patients?
Interested to know how this practice may vary at particular centers.
Answer from: at Academic Institution
We have incorporated blinatumomab for most patients as two non-consecutive cycles. Once in maintenance, we have not uniformly added blinatumomab, although we have interrupted maintenance to offer blinatumomab to select patients (high-risk genetics or those who had significant treatment modifications...
Sign in or Register to read more